The STS-J01 study, a collaborative effort across 11 institutions in Japan, specifically evaluated PEDMARK’s ability to reduce cisplatin-induced ototoxicity in children and AYA patients diagnosed with non-metastatic solid tumors. This research builds upon previous international studies, providing a crucial regional perspective and expanding the demographic and geographical scope of data supporting sodium thiosulfate. The results are particularly vital given the profound long-term impact of hearing loss on young patients’ development and quality of life.

Key Findings from the STS-J01 Study: A Significant Reduction in Ototoxicity

The study enrolled a total of 33 patients, with 27 included in the primary cohort and an additional six in exploratory cohorts. For the primary efficacy analysis, 25 patients were assessed, revealing a striking outcome: only 24% (6 of 25) developed hearing loss according to the stringent American Speech-Language-Hearing Association (ASHA) criteria. This figure represents a dramatic improvement when benchmarked against a prespecified historical rate of 56.4% for similar patient populations receiving cisplatin without otoprotection. The statistical significance of this difference (P=0.001) firmly establishes PEDMARK’s protective effect.

Further analysis using the widely recognized Brock grading criteria demonstrated even more favorable results, with 84% of patients experiencing Grade 0 hearing loss, indicating no clinically significant impairment. Crucially, the study reported no instances of Grade 3 or Grade 4 hearing loss, the most severe classifications that often necessitate lifelong hearing aids or cochlear implants. This absence of severe ototoxicity is a major clinical triumph, as these grades are particularly devastating for young individuals.

The STS-J01 trial was structured as an open-label, single-arm study, meaning that the observed hearing outcomes were rigorously compared against a robust, prespecified historical benchmark rather than a concurrent randomized control group. This design, while distinct from a randomized controlled trial, is often employed in situations where the standard of care (cisplatin without otoprotection) carries such a high risk of adverse events that withholding a potentially beneficial intervention would be ethically challenging. Patients in the study received PEDMARK intravenously approximately six hours after cisplatin infusion, with dosing meticulously adjusted based on individual body weight. This specific timing has been a consistent element across studies examining PEDMARK’s efficacy, hinting at a critical mechanistic window.

Maintaining Antitumor Activity and Mechanistic Insights

A paramount concern in any supportive care intervention for cancer patients is ensuring that the protective measure does not compromise the primary anti-tumor efficacy of the chemotherapy. The STS-J01 study addressed this directly, reporting objective tumor responses in an impressive 23 out of 24 evaluable patients, translating to a 95.8% response rate. This robust anti-tumor activity alongside significant otoprotection reinforces the notion that PEDMARK can be safely integrated into existing cisplatin-based chemotherapy regimens without diminishing their life-saving potential.

Moreover, the study incorporated prospective pharmacokinetic (PK) analyses, which offered valuable mechanistic insights. These analyses further supported the established six-hour interval between cisplatin and PEDMARK administration. As explained by Dr. Pierre S. Sayad, Chief Medical Officer at Fennec Pharmaceuticals, "The prospective pharmacokinetic analyses provide additional insight into why the six-hour interval matters, supporting a model in which PEDMARK acts on residual circulating and exchangeable platinum after cisplatin has had time to distribute and initiate its antitumor activity." This understanding is crucial for optimizing treatment protocols and ensuring maximum efficacy for both the chemotherapy and the otoprotective agent. It suggests that PEDMARK intervenes once cisplatin has largely completed its initial therapeutic action, scavenging remaining platinum species that would otherwise accumulate in and damage the delicate cochlear cells.

The Pervasive Threat of Cisplatin-Induced Ototoxicity

Cisplatin and other platinum-based chemotherapies are cornerstones in the treatment of a wide array of solid tumors, including osteosarcoma, hepatoblastoma, neuroblastoma, germ cell tumors, and medulloblastoma, which frequently affect pediatric and AYA populations. While indispensable for their potent anti-cancer properties, these agents are notorious for causing permanent and irreversible hearing loss, a condition known as ototoxicity. Published studies have consistently estimated that between 60% and 90% of patients treated with cisplatin may develop some degree of hearing impairment. The exact incidence and severity are influenced by a complex interplay of factors, including the cumulative dose and duration of treatment, individual genetic predispositions, age at treatment, and concurrent exposure to other ototoxic agents.

For many patients, the resulting hearing loss is severe enough to necessitate lifelong interventions such as hearing aids or, in more extreme cases, cochlear implants. The implications are particularly profound for children and young people. In this critical developmental stage, treatment-related hearing loss can significantly impede speech and language acquisition, adversely affect academic performance, disrupt social-emotional development, and negatively impact overall quality of life. The challenges extend beyond audiological issues, influencing educational attainment, career prospects, and social integration. The burden of ototoxicity often represents a cruel trade-off for survival, highlighting a significant unmet medical need in pediatric oncology for decades. Before the advent of effective otoprotective strategies, oncologists were often forced to balance the life-saving potential of cisplatin against the certainty of irreversible hearing damage, a dilemma that weighed heavily on both clinicians and families.

PEDMARK’s Global Journey: A Timeline of Approvals and Expanding Access

The positive data from the STS-J01 study in Japan adds a new chapter to the growing narrative of PEDMARK’s development and global recognition. PEDMARK (sodium thiosulfate injection) is the first and only FDA-approved therapy specifically designed to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients.

The journey of PEDMARK has been marked by several significant milestones:

  • Pivotal Phase 3 Trials: PEDMARK’s efficacy and safety were initially established through two randomized Phase 3 clinical trials: the Children’s Oncology Group Protocol ACCL0431 and the SIOPEL 6 study. These groundbreaking studies demonstrated that delayed administration of sodium thiosulfate could significantly reduce hearing loss without compromising cisplatin’s anti-tumor activity. The ACCL0431 trial, for instance, showed a substantial reduction in hearing loss incidence, with patients receiving sodium thiosulfate experiencing a lower rate of ototoxicity compared to those who did not. Similarly, the SIOPEL 6 study, focusing on hepatoblastoma, confirmed these benefits.
  • FDA Approval (September 2022): Based on the compelling evidence from these pivotal trials, PEDMARK received approval from the U.S. Food and Drug Administration (FDA) in September 2022. This approval specifically covered pediatric patients one month of age and older with localized, non-metastatic solid tumors, marking a monumental step forward in supportive care for young cancer patients in the United States.
  • NCCN Recommendation: Recognizing its broad utility, PEDMARK also received a Category 2A recommendation from the National Comprehensive Cancer Network (NCCN) for use in adolescent and young adult (AYA) patients. This endorsement highlights its applicability beyond the youngest pediatric cohorts, addressing the needs of a wider age range.
  • European and UK Approvals (2023): Expanding its global reach, PEDMARK received European Commission approval in June 2023 and United Kingdom approval in October 2023, where it is marketed under the brand name PEDMARQSI®. These approvals opened doors for patients across Europe and the UK to benefit from this innovative otoprotective therapy.
  • Norgine Licensing Agreement (March 2024): To facilitate widespread commercialization and patient access, Fennec Pharmaceuticals entered into an exclusive licensing agreement with Norgine Pharmaceuticals Ltd. in March 2024. This partnership empowers Norgine to commercialize PEDMARQSI® across Europe, the U.K., Australia, and New Zealand, ensuring that the treatment reaches a broader patient population. As a result, PEDMARQSI is now commercially available in multiple countries, marking a significant achievement in global health equity for pediatric cancer survivors.
  • Japanese Data (September 2024): The current STS-J01 study from Japan further reinforces this global trajectory, providing crucial data from an Asian population and adding another robust dataset to the growing body of evidence. This regional validation is particularly important for regulatory processes and clinical adoption in Japan and potentially other Asian markets.

The consistent findings across diverse populations and study designs underscore the reliability and broad applicability of PEDMARK. Each approval and new dataset contributes to a comprehensive understanding of sodium thiosulfate’s role in mitigating cisplatin-induced ototoxicity, solidifying its position as a standard of care.

Fennec Pharmaceuticals’ Commitment and Future Outlook in Japan

Fennec Pharmaceuticals, a specialty pharmaceutical company dedicated to addressing ototoxicity in cancer patients, expressed strong enthusiasm for the STS-J01 results. Dr. Pierre S. Sayad, the company’s Chief Medical Officer, reiterated the significance of the findings: "The clinical and pharmacologic findings of STS-J01 are compelling. We observed a significant reduction in hearing loss, with no Grade 3 or Grade 4 hearing loss by Brock criteria, alongside a 95.8% objective response rate in evaluable patients." His comments highlight both the safety and efficacy aspects crucial for widespread adoption.

The safety profile observed in the STS-J01 study was consistent with PEDMARK’s known tolerability profile and the expected toxicities associated with cisplatin-containing chemotherapy. Critically, no serious adverse events were attributed to PEDMARK, and investigators reported no Grade 4 PEDMARK-related toxicity. This favorable safety profile, combined with the maintained anti-tumor activity, is a key factor in ensuring clinicians can confidently integrate PEDMARK into aggressive chemotherapy regimens without undue concern for additional severe adverse effects.

Fennec Pharmaceuticals is actively pursuing registration for PEDMARK in Japan, leveraging the compelling data from the STS-J01 study. The company is also exploring potential partnering or licensing opportunities within the country to ensure efficient and widespread access for Japanese patients. The successful commercialization strategy employed in Europe and other regions through partnerships like that with Norgine Pharmaceuticals could serve as a blueprint for its expansion into the Japanese market. The addition of the Japanese dataset is not merely a scientific confirmation but a strategic imperative, paving the way for regulatory approval and market entry in a key global pharmaceutical market.

Broader Implications for Pediatric Oncology and Quality of Life

The STS-J01 results, in conjunction with the ACCL0431 and SIOPEL 6 studies, represent a powerful validation that delayed PEDMARK administration does not interfere with cisplatin’s crucial antitumor activity. This consistent finding across multiple studies and diverse patient populations is paramount, as it removes a major barrier to widespread clinical adoption. Oncologists can now more confidently prescribe cisplatin, knowing that a proven method exists to protect their young patients’ hearing without compromising their chances of survival.

The implications for pediatric oncology are profound. Mitigating cisplatin-induced hearing loss significantly enhances the long-term quality of life for cancer survivors. Children who retain their hearing are better equipped for academic success, social integration, and overall developmental milestones. The psychological burden on families is also eased, as they no longer have to grapple with the devastating side effect of a life-saving treatment. This progress underscores a broader shift in cancer care, moving beyond mere survival to encompass a holistic approach that prioritizes the long-term well-being and functional outcomes of patients, particularly vulnerable populations like children and young adults.

The continued research into the prevention of cisplatin-induced hearing loss, exemplified by studies like STS-J01, highlights an ongoing commitment within the medical community to address the often-overlooked long-term consequences of cancer treatment. As cancer survival rates continue to improve for pediatric and AYA patients, the focus on supportive care and the mitigation of treatment-related morbidities becomes increasingly vital. PEDMARK represents a significant stride in this direction, offering hope for a future where young cancer survivors can not only overcome their disease but also thrive with their hearing intact. This advancement is a testament to the power of targeted research and collaborative efforts in transforming patient care globally.